论文部分内容阅读
AIM: To study the degradation or absorption of recombinanthuman epidermal growth factor (rhEGF) in a closed stomach orintestinal segment for the developing as cytoprotective drug forpeptic ulcer. METHODS: ~(125)I-rhEGF (4O μg·kg-~(-1)) wereadministrated through the upper opening of the closed segment ofstomach or intestine of the anaesthetized rats in situ, and sampleswere obtained from the lower opening at various times afterdosing. Concentration was determined by ~(125)I-radiolablling andreversed phase high performance liquid chromatographic analysis
AIM: To study the degradation or absorption of recombinant human epidermal growth factor (rhEGF) in a closed stomach or intestinal segment for the developing as cytoprotective drug forpeptic ulcer. METHODS: ~ (125) I-rhEGF (40 μg · kg -1 )) wereadministrated through the upper opening of the closed segment of gastric or intestine of the anaesthetized rats in situ, and sampleswere obtained from the lower opening at various times afterdosing. Concentration was determined by ~ (125) I-radiolabeling and reversed phase high performance liquid chromatographic analysis